

# Developmental Exposure to Silver Nanoparticles Leads to Long Term Gut Dysbiosis and Neurobehavioral Alterations

Zhen Lyu

University of Missouri

Shreya Ghoshdastidar

University of Missouri

Karamkolly Rekha

University of Missouri

Dhananjay Suresh

University of Missouri

Jiude Mao

University of Missouri

Nathan Bivens

University of Missouri

Raghuraman Kannan

University of Missouri

Trupti Joshi

University of Missouri

Cheryl Rosenfeld

University of Missouri

Upendran Anandhi (✉ [upendrana@health.missouri.edu](mailto:upendrana@health.missouri.edu))

University of Missouri

---

## Research Article

**Keywords:** Developmental effects, Microbiome-gut-brain-axis, Microbiota, Neurobehavioral alterations, DOHaD.

**Posted Date:** December 4th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-114695/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Scientific Reports on March 22nd, 2021.  
See the published version at <https://doi.org/10.1038/s41598-021-85919-7>.

# **Developmental Exposure to Silver Nanoparticles Leads to Long Term Gut Dysbiosis and Neurobehavioral Alterations**

Author information

Zhen Lyu<sup>Ψ,1</sup>, Shreya Ghoshdastidar<sup>Ψ,2</sup>, Karamkolly R. Rekha<sup>Ψ,3</sup>, Dhananjay Suresh<sup>2</sup>, Jiude Mao<sup>4,7</sup>, Nathan Bivens<sup>5</sup>, Raghuraman Kannan<sup>2,3</sup>, Trupti Joshi<sup>1,6,7,8\*</sup>, Cheryl S. Rosenfeld<sup>4,7,8,9,10,11\*</sup>, Anandhi Upendran<sup>11,12\*</sup>

<sup>Ψ</sup> Equal contributing authors

Author affiliation

Departments of <sup>1</sup>Electrical Engineering and Computer Science, <sup>2</sup>Bioengineering, <sup>3</sup>Radiology, <sup>4</sup>Biomedical Sciences, <sup>5</sup>DNA Core Facility, <sup>6</sup>Health Management and Informatics, <sup>7</sup>MU Institute of Data Science and Informatics, <sup>8</sup>Bond Life Sciences Center, <sup>9</sup>Genetics Area Program, <sup>10</sup>Thompson Center for Autism and Neurobehavioral Disorders, <sup>11</sup>Medical Pharmacology & Physiology and <sup>12</sup>MU-Institute of Clinical and Translational Science, University of Missouri, Columbia, Missouri 65212, USA.

\*Correspondence: [UpendranA@health.missouri.edu](mailto:UpendranA@health.missouri.edu); [RosenfeldC@missouri.edu](mailto:RosenfeldC@missouri.edu); [JoshiTr@health.missouri.edu](mailto:JoshiTr@health.missouri.edu)

Keywords: Developmental effects, Microbiome-gut-brain-axis, Microbiota, Neurobehavioral alterations, DOHaD.

## ***Abstract***

Due to their antimicrobial properties, silver nanoparticles (NPs) are used in a wide range of consumer products that includes topical wound dressings, coatings for biomedical devices, and food-packaging to extend the shelf-life. Despite their beneficial antimicrobial effects, developmental exposure to such NPs may lead to gut dysbiosis and long-term health consequences in exposed offspring. Silver NPs can cross the placenta and blood-brain-barrier to translocate in the brain of offspring. The underlying hypothesis tested in the current study was that developmental exposure of male and female mice to silver NPs disrupts the microbiome-gut-brain axis. To examine for such effects, C57BL6 female mice were exposed orally to silver NPs at a dose of 3 mg/kg BW or vehicle control two weeks prior to breeding and throughout gestation. Male and female offspring were tested in various mazes that measure different behavioral domains, and the gut microbial profiles were surveyed from 30 through 120 days of age. Our study results suggest that developmental exposure results in increased likelihood of engaging in repetitive behaviors and reductions in resident microglial cells. Echo-MRI results indicate increased body fat in offspring exposed to NP exhibit. *Coprobacillus spp.*, *Mucispirillum spp.*, and *Bifidobacterium spp.* were reduced, while *Prevotella spp.*, *Bacillus spp.*, *Planococcaceae*, *Staphylococcus spp.*, *Enterococcus spp.*, and *Ruminococcus spp.* were increased in those developmentally exposed to NPs. These bacterial changes were linked to behavioral and metabolic alterations. In conclusion, developmental exposure of silver NPs results in long term gut dysbiosis, body fat increase and neurobehavioral alterations in offspring.

## ***Introduction***

Engineered nanomaterials are used for a myriad of applications due to their unique properties. At the nanoscale level, the number of surface atoms is much higher than the bulk of the material. The large number of surface atoms in metallic nanoparticles is responsible for increased reactivity and unique photophysical properties. Nanoparticles within the size domains of 1-100 nanometers exhibit exceptional properties compared to source metals that make them suitable for various applications, including sensors, optoelectronic materials, and drug delivery devices.<sup>1</sup> Among nanomaterials that have been widely used for several applications, silver nanoparticles exhibit antimicrobial and anti-fungal activity. Silver nanoparticles (NP) are used for several biomedical applications and contained within consumer products that include topical wound dressings, coatings for biomedical devices, fabrics, food-packaging to extend the shelf-life and reduce potential growth of pathogenic bacteria, as dietary health supplements, and as antimicrobial coating in several children's products.<sup>2-16</sup> In spite of their beneficial antimicrobial effects, long-term exposure to these particles can cause deleterious health outcomes, including metabolic alterations, immunological changes, reproductive and importantly, gut alternations and neurotoxicity related through the microbiome-gut-brain axis.<sup>16-27</sup> A detailed biodistribution study following silver NP exposure have reported accumulation and toxicity effects to at the site of usage and in distal organs, especially the brain.<sup>26</sup> The study pointed out the need of understanding the mechanisms of specific organ toxicities due to silver NP.<sup>28</sup> A recent report on *hazard* characterization of silver NP suggest that they may cause neuro- and reproductive toxicity, as such particles may persist for longer periods.<sup>29</sup> According to a recent study the intake of silver in humans could be as high as 90 µg/day.<sup>30</sup> It has also been estimated that a child's

potential non-dietary ingestion exposure to silver NPs when drinking formula from a sippy cup is ~ 1.53  $\mu\text{g Ag/Kg}$ .<sup>31</sup>

Silver NP from the consumer products can leach into the environment and get exposed to human and other animals *via* inhalation, ingestion, or dermal contact.<sup>32</sup> Among these exposures, dietary ingestion is considered the primary route of exposure to silver nanoparticles.<sup>33</sup> Prolonged exposure of silver NP may cause several developmental changes to the offspring through direct exposure or placental transfer.<sup>28, 34-43</sup> Developmental exposure of rodent models to silver NPs has revealed changes in offspring organ development, such as in the fetal brain and mitochondrial disruptions leading to oxidative stress. However, detailed information on the developmental effects are still lacking and is an area of key interest.<sup>44</sup>

Extensive studies in zebrafish (*Danio rerio*), fruit flies (*Drosophila melanogaster*), and Mediterranean Sea urchins (*Arbacia lixula*) reveals that developmental exposure to silver NPscan lead to neurobehavioral alterations, gut-dysbiosis and other disturbances.<sup>45-54</sup> Select studies have also suggested that perinatal exposure to silver NPs can affect neurobehavioral programming and other offspring parameters in rodent models<sup>36, 43, 55-57</sup>, although more work is needed to understand the potential health effects in mammals of developmental exposure to such compounds.

Silver NP can accumulate in the gastrointestinal (GI) tract, whereupon they can circulate to the brain. Recent findings support the notion that silver NPs accumulate in the brain after oral exposure, which indicates NPs might penetrate the blood-brain barrier (BBB) or be transmitted to the brain via retrograde axonal transmission.<sup>58</sup>

Besides targeting the host, silver and other NPs can affect the gut microbiome, although not all studies agree as to which bacteria if any are susceptible to such effects.<sup>33</sup> One study

showed that rats orally exposed to silver NPs show decreased populations of *Firmicutes* and *Lactobacillus* but greater proportion of gram negative bacteria, which tend to be more pathogenic in the GI system.<sup>33</sup> Another study using next generation sequencing (NGS) technique demonstrated that oral exposure of silver NPs results in dose-dependent decreases in total gut microbiota composition and alterations in the proportion of specific bacterial species.<sup>59</sup> Examination of the effects of silver NPs on a defined bacterial community established from a healthy human donor reveals that these particles negatively influence the gut flora.<sup>60</sup>

In our previous study, we found that direct exposure of rats to silver NPs of different shapes such as cubes and spheres had an influence on the gut flora. Cube shaped silver NPs decreased *Clostridium spp.*, *Bacteroides uniformis*, *Christensenellaceae*, and *Coprococcus eutactus* whereas, sphere shaped NPs reduced the relative concentrations of *Oscillospira spp.*, *Dehalobacterium spp.*, *Peptococcaeae*, *Corynebacterium spp.*, *Aggregatibacter pneumotropica*.<sup>61</sup> While it is clear that direct exposure to silver and other NPs can affect gut microbiota, it is not clear if silver NPs can exert effect on gut bacterial populations of mammalian offspring developmentally exposed to them and whether early exposure to such environmental chemicals can lead to long-term disturbances in the gut flora, otherwise considered gut dysbiosis. In *Drosophila melanogaster*, developmental exposure to copper or silver NPs, reduced progression to the larval and pupal stages, and larval climbing ability.<sup>48</sup> Correspondingly, developmental exposure to silver NPs reduced the overall diversity of gut microbiota relative to control larvae with those exposed to silver NPs containing increased relative amounts of *Lactobacillus brevis* but reduced amounts *Acetobacter* relative to controls.<sup>48</sup>

It is important to understand how silver NPs and other environmental chemicals affect gut microorganisms as it is increasingly becoming apparent that shifts in gut bacteria can affect

host health, especially neural development and correspondingly risk for neurobehavioral disorders, such as autism spectrum disorders (ASD). The intimate connection between the gut, microbiome, and brain has given rise to the term the microbiome-gut-brain axis.<sup>62-65</sup> The term implies that crosstalk exists between the gut microbiota and brain with bacteria within the intestines able to modulate neurobehavioral responses, which could be due to direct effects of the bacteria, bacterial metabolites and other products that mimic host function, such as neurotransmitters, and/or stimulation of host inflammation.

The overarching hypothesis thus tested in the current study was that developmental exposure through the dam to silver NPs can affect neurobehavioral programming and the microbiome-gut-brain axis. To test this hypothesis, female mice were exposed to silver NPs or vehicle control two weeks prior to breeding and throughout gestation. Offspring were tested in various mazes that measure different behavioral domains, and the gut microbial profiles were surveyed from 30 through 120 days of age.

## ***Methods***

Materials used in these studies, surface coating and dosage of silver nanoparticles, sample preparation for silver quantification by ICP-OES, methods for Barnes maze, elevated plus maze (EPM), body composition analysis, brain histopathological analyses and morphometric quantification, collection of fecal samples, isolation of fecal microbial DNA, and 16s rRNA sequencing are included in Supplementary material.

### *Synthesis of Silver Nanoparticles*

Silver NP were synthesized based on a previously published procedure but with some modifications<sup>66</sup>. Briefly, sodium borohydride (10 mg; 26 mM) was dissolved in 10 ml distilled

water and stored in dark at 4°C for 30 min. Simultaneously, silver nitrate (42.4 mg; 2.5 mM) was dissolved in 100 ml deionized water in a 500 ml conical flask with vigorous stirring. Sodium citrate (40 mg; 3.1 mM) was dissolved in 100 ml DIW in 250 ml conical flask and added to silver nitrate solution and stirred vigorously for 5 minutes. Subsequently, 600 µl of sodium borohydride (2.5 mM) solution was added to the solution dropwise and stirred vigorously for 10 minutes. The color of the solution gradually changed to yellow. The temperature of the solution was then slowly increased to 100°C and maintained for 90 minutes. At this point, the color of the solution was yellowish brown. The solution was cooled to room temperature and then kept in 4°C overnight to allow the nanoparticles to grow. For the animal studies, three batches of 10X nanoparticle were prepared and pooled together. The pooled nanoparticle batch was passed through Minimate Tangential Flow Filtration (TFF) PALL filter (1 KD). The resulting concentrated, filtered solution was stored in 4°C until further use. The pH of the nanoparticle solution was adjusted to pH 6.5 for animal studies.

### *Animal Husbandry and Treatments*

All animal studies were conducted according to University of Missouri approved Animal care and Use Committee protocols (protocol # 9590). The University of Missouri is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International). Mice were maintained under a 12:12 h light/dark cycle at  $21 \pm 1^\circ\text{C}$  and  $50 \pm 5\%$  humidity. Standard laboratory diet (AIN93G phytoestrogen-free diet with 7% corn oil, Envigo, Madison, WI) and drinking water were available *ad libitum*. Twenty Female C57BL6 and 10 Male aged 4-5 weeks were purchased from Charles River and acclimatized for a period of one

week. Female mice were randomly divided into control and NP groups. Each group included 10 breeder females.

After one-week of acclimatization, female mice in NP group received daily and oral administration of 3 mg/Kg body weight (BW) of NP (200  $\mu$ l, 0.4mg/ml) *via* 18-gauge 75mm long disposable gauge needles (Instech, Plymouth Meeting, PA). The control animals were dosed with same volume of sterile water (200  $\mu$ l) as that of received by the NP group. After one week of receiving these treatments, females were paired with breeder males. Treatment with NP or water extended through gestation and ended at parturition. At 21 days of age, offspring were weaned. At this time, two male and two female offspring were randomly selected from each litter for follow-up gut microbiome and behavioral studies.

#### *Bioinformatics and amplicon analyses*

Paired-end Illumina MiSeq DNA reads were joined using `join_paired_ends.py` and combined using `add_qiime_labels.py` from QIIME 1.9.1<sup>67</sup>. Uclust<sup>68</sup> was used to clean contigs and remove those with  $E > 0.5$ , ([http://drive5.com/usearch/manual/exp\\_errs.html](http://drive5.com/usearch/manual/exp_errs.html)). Contigs were clustered to 97% identity against DNA sequences in the Greengenes database<sup>69</sup>, version 13\_8, using the QIIME<sup>70</sup>, version 1.9.1, script `pick_open_reference_otus.py`, which obviates chimera and PCR error detection with all reads clustered. After OTU selection, we filtered out OTUs with  $\leq$  ten observation counts using the script `filter_otus_from_otu_table.py`.

Microbial diversity was evaluated by running alpha diversity and beta diversity on the OUT tables. Diversity analysis was conducted for each of the time points group (30, 60, 90 and 120 Days) using the q2-diversity plugin from QIIME2. The diversity comparisons were assessed between control and nanoparticles group. Firstly, biom format OTUs files were

converted to QZA format used by QIIME2<sup>71</sup> using “qiime tools import” command from QIIME2 package. For alpha diversity, Shannon’s diversity index (a quantitative measure of community richness), Observed OTUs (a qualitative measure of community richness) and Faith’s Phylogenetic Diversity (a qualitative measure of community richness that incorporates phylogenetic relationship between the features) values and rarefaction matrices were calculated and plotted using the “qiime diversity alpha-rarefaction” command supported by the QIIME2. Measurements of beta-diversity were facilitated by the QIIME2 command “qiime diversity core-metrics-phylogenetics” with PCoA plots generated. Visualization of taxonomy bar-charts were generated using “qiime taxa barplot” command in QIIME2.

LEfSe (Linear discriminant analysis effect size)<sup>72</sup> was used to detect significant features. It combines the statistical test (Kruskal-Wallis test, pairwise Wilcoxon test) with linear discriminate analysis for feature selection and ranks feature by effect size. The alpha value employed for the factorial Kruskal-Wallis test and pairwise Wilcoxon test is 0.05. The threshold employed on the logarithmic LDA (Linear discriminant analysis) score for discriminative feature is 2.0.

### *Microbial profiles temporal changes*

In order to examine how the microbiome profiles changes over time, we co-assembled the abundant matrix for all samples. Average value of the significant taxa for each time group (30, 60, 90, and 120 days of age) was calculated to generate the circular plots using the *anvi*-interactive command in the *Anvi'o*<sup>73</sup> tool. Each circular plot contains six layers. The auxiliary layers from the inside out include the bacterial genera and taxonomy name. The grey or black bars represent taxonomy abundance at 30, 60, 90, and 120 day of age.

### *Functional metagenomics predictions*

Bacterial metabolic characterization of sample types was facilitated with PICRUSt (the phylogenetic investigation of communities by reconstruction of unobserved states),<sup>74</sup> version 1.1.4. We used the `filter_otus_from_otu_table.py` script from QIIME and Greengenes database (13\_5\_release) to discard any reads that did not hit the reference collections.

`Normalize_by_copy_number.py` script was used to normalize the OTU table by dividing each known/predicted 16S copy number abundance. The final metagenome functional predictions were predicted using `predict_metagenomes.py` script. We collapsed the results table, consisting of Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthologs (KOs) at KO level 3 within the pathway hierarchy of KEGG using the `categorize_by_function.py` script. DESeq2<sup>75</sup> was used to highlight the KEGG terms that are significantly differentially abundant between control and NP samples with  $p < 0.1$ .

### *Correlation of taxa abundance and metabolic activity abundance*

To correlate the taxa abundance with metabolic characteristics of sample types, a custom R script provided as a gift from Dr. Jun Ma and Kjersti Aagaard-Tillery, Baylor College of Medicine, Houston, TX was used, as we have done previously.<sup>61, 76, 77</sup> In these figures, the correlation of the abundance of taxa (from the OTU table) with the predicted metabolic function (from KEGG pathways as determined by PICRUSt), was calculated with the R stats function `cor.test` (<https://cran.r-project.org/>), using the Kendall method, a rank-based measure of association. The `cor.test` function outputs the correlation coefficient and significance of a comparison of an OTU with a KEGG term across samples. The matrix of all the correlation

values was visualized using the R package corrplot (<https://cran.r-project.org/>). The area and intensity change together so that larger, darker, circles represent correlation coefficients that are larger in magnitude. The scale to the right of each figure relates those shades of color to the value of the correlation coefficient. Up to 53 of the most abundantly represented KEGG terms that had a significant ( $\alpha < 0.05$ ) correlation with one or more taxa were included in the plot.

### *Multi-omics integrative correlation analyses*

We used the mixOmics R package<sup>78</sup> to correlate the bacterial genera changes simultaneously with body composition, brain histological data and behavioral results, which enabled the integration of the microbiome, behavioral (Barnes, EPM), histology (Nissl and glial staining) and Echo results. We conducted sparse discriminant analysis with partial least square regression with function ‘block.splsda’. The circos plot was generated by using the ‘circosPlot’ function with correlations calculated using the method from González, et al.<sup>79</sup> and 0.7 correlation was used as the cutoff.

### *Statistical analyses for histology and behavioral data*

All dependent variables including social behaviors, Barnes maze, such as latency to find correct escape hole, and travel speed, EPM data, such as time spent in open/closed arms, head dipping and rearing, were analyzed as a split plot in space and time, as detailed in our previous studies<sup>80, 81</sup> and by using SAS version 9.4 program (SAS Institute, Cary, NC).

Barnes data was analyzed by using a repeated measurement design with PROC GLIMMIX. Barnes maze Latency data (as determined by the experimenter and the software program) were additionally analyzed by using a Proportional Hazard Ratio (PROC PHREG in

SAS, Version 9.4, SAS Institute), as detailed previously. This analysis adjusts for right-censoring (defined here as not locating the escape hole within the allotted time) while still accommodating the study design. Effects are reported as a hazard ratio that represents the odds of a subject developmentally exposed to silver NPs finding the escape hole compared to individuals in the control group. A significant result indicates the odds are not 1:1. A result greater than 1 indicates the NP exposed group found the escape hole more quickly than the control group. A result smaller than 1 indicates that the NP exposed group found the escape hole more slowly compared to the control group. The litter was again used as the denominator of F for treatment, sex, day, and all possible interactions. These data are reported as the 95% lower confidence limit, mean, and 95% upper confidence limit. Treatment effects were tested with dam as the experimental unit and error term. Differences between treatment and control groups were determined by Fisher's protected least-significant difference (LSD). The LSD was only calculated if the overall F test was significant.<sup>82, 83</sup> A *p* value of  $\leq 0.05$  was considered significant. All data are presented as actual means ( $\bar{x}$ ) and standard error of the means (SEM).

## ***Results***

### *Synthesis and characterization of Nanoparticles*

Silver NPs were synthesized following slight modification of reported procedure.<sup>66</sup> Silver NP were formed by the reduction of silver nitrate using sodium borohydride and sodium citrate as the stabilizer. The reagents were proportionally increased to prepare 10X concentration, and the final solution was concentrated by PALL (1KD) filtration procedure. Dialysis was performed on concentrated silver nanoparticles to remove silver ions and the dialysates were used for the study.<sup>61</sup> The concentrated NP were characterized using TEM, Dynamic Light

Scattering (DLS) and UV-visible spectroscopy. TEM images confirmed the formation of highly dispersed and uniformly distributed spherical NP with an average core size of  $18 \pm 1.8$  nm and characteristic surface plasmon resonance peak was observed at 400 nm (**Figure S1**). The hydrodynamic diameter ( $15.8 \pm 3.4$  nm) and negative zeta potential ( $-32 \pm 1.2$  mV) are suggestive of highly stable and uniform particulate nature of the particles in solution. The increased absorbance of the NP confirmed the formation of NP at a higher concentration. Animals tolerated oral administration, and no observable changes were observed during the dosing periods. No morbidities or mortalities were observed in the female mice in the NP or control group.

#### *Barnes Maze*

As shown in **Figure S2**, latency to reach the escape hole and distance travelled was surprisingly reduced for mice developmentally exposed to NP compared to control group (Latency:  $115.31 \pm 8.52$  seconds and  $126.19 \pm 7.79$  seconds respectively,  $p = 0.05$ ; Distance Traveled:  $7.34 \pm 0.58$  m and  $8.42 \pm 0.54$  m, respectively,  $p = 0.01$ ). However, there was no difference in velocity between the NP treated offspring and control groups. To further examine the differences that were evident for latency, the data were re-analyzed by using a Hazard Ratio analysis, which as detailed in the methods section, controls for those animals that did not find the maze in the allotted 300 seconds. This approach was also used to analyze the results per each day of the five-day trial period (**Figure S3**). Silver NP exposed offspring were more likely to find the escape hole than controls on Day 4 (1.81;  $p = 0.04$ ), and this trend continued through Day 5 (1.38;  $p = 0.06$ ).

### *Elevated Plus Maze (EPM)*

Mice developmentally exposed to NP spent more time engaged in stereotypic head dipping behaviors relative to controls ( $132.75 \pm 21.11$  seconds and  $81.65 \pm 11.08$  seconds, respectively;  $p = 0.02$ , **Figure 1a**). Rearing is considered another stereotypical behavior. However, mice developmentally exposed to NP, had lower frequency of rearing ( $0.75 \pm 0.13$  n/s), compared to controls ( $1.39 \pm 0.27$  #/s,  $p = 0.05$ ) and thus, the average time spent rearing by mice treated with NP ( $146.81 \pm 27.68$  seconds, **Figure 1b**) was reduced compared to controls ( $201.71 \pm 21.02$  seconds;  $p = 0.002$ ). The incidences of remaining immobile during the testing period were lower in NP treated offspring ( $0.50 \pm 0.21$  n/s) relative to controls ( $0.18 \pm 0.02$  #/s;  $p < 0.05$ ) (**Figure 1c**). None of the other parameters, including number and duration of time spent in the different arms or center differed between the two groups (**Table S2**).

### *Histopathology*

Neuronal cell counts, as determined by Nissl staining, for the NP treated ( $6183.75 \pm 1000.96$ ) and control group offspring ( $5613.73 \pm 1245.27$ ; **Figure 2a**) were similar. However, the microglial counts were reduced in the NP treated offspring ( $4838.27 \pm 293.96$ ) compared to the controls ( $6681.92 \pm 824.31$ ,  $p = 0.05$ , **Figure 2b**). Brain sections containing hippocampus stained with Nissl dye for neurons and *anti*-TMEM for microglial cells are shown in **Figure S4**.

### *Echo MRI*

Mice developmentally exposed to NP had increased fat content ( $6.20 \pm 1.01$ g) relative to controls ( $4.11 \pm 0.47$  g;  $p = 0.01$ , **Figure 3a**). Total water content for mice developmentally exposed to NP ( $16.76 \pm 0.60$  g) was slightly higher than control group ( $15.96 \pm 0.56$  g;  $p = 0.03$ ) as shown

in **Figure 3b**. No significant differences were observed in total lean mass, lean percentage, free water, free water percentage and total water percentage (**Table S3**).

### *Gut Microbiota*

We first considered whether developmental exposure to silver NP altered the  $\alpha$ - and  $\beta$ -diversity at 30, 60, 90, and 120 days of age. Shannon analysis revealed no differences based on treatment at any of these ages in  $\alpha$ -diversity (**Figure S5**). However, 3D PCA analyses reveal clear separation based on treatment group with the PERMANOVA values ranging on these days from  $p = 0.001$  to 0.03 (**Figure 4**).

As the behavioral studies were conducted between 90 and 120 days of age, we further pursued those bacteria that differed at 120 days of age by analyzing the data with LEfSe analyses. As shown in **Figure 5**, developmental exposure to silver NP resulted in the relative expression of several bacteria increasing, although there were select ones that were downregulated due to this exposure. Examples of bacteria that were upregulated in the NP group include *Bacteroides spp.*, *Bacillus spp.*, *Ruminococcus spp.*, *Planococcaceae*, *Enterococcus spp.*, *Prevotella spp.*, *Staphylococcus spp.*, *Streptococcus spp.*, *Christensenellaceae*, and *Enterococcaceae*. In contrast, *Coprobacillus spp.*, *Mucispirillum spp.*, and *Bifidobacterium spp.*, were reduced in those developmentally exposed to NP.

In order to examine how the microbiome profiles changes over time, circular plots using the Anvi'o program<sup>73</sup> were generated. Each circular plot contains six layers. The auxiliary layers from the inside out include the bacterial genera and specific taxonomy name. The grey or black bars represent taxonomy abundance at 30, 60, 90, and 120 day of age. As shown by increasing amount of black, *Bifidobacterium spp.* is moderately present in controls at 30, 60,

and 90 days of age, and then dramatically increases at 120 days of age (**Figure S6**). However, this bacterium is less abundant in those developmentally exposed to NP at all ages examined. *Bacteroides spp.* is plentiful in control and NP at all ages examined. The relative abundance of *Prevotella spp.* is greatest at 30 days of age in controls and NP and decreases thereafter. *Mucispirillum spp.* relative abundance is most plentiful in controls at 30 and 120 days of age; whereas, in NP, this bacterium peaks at 60 days age. In controls, *Ruminococcus spp.* is abundant at 30 days of age and declines thereafter. In contrast, this bacterium is abundant at 60 days of age in NP group and declines but still present at 90 and 120 days of age.

Correlation of PICRUSt analysis with bacterial changes reveals that the most significant metabolite associations are with those bacteria upregulated in the NP, including *Prevotella spp.*, *Bacillus spp.*, *Planococcaceae*, *Staphylococcus spp.*, *Enterococcus spp.*, and *Ruminococcus spp.* (**Figure 6**). For *Prevotella spp.*, example KEGG pathways and metabolites that were inversely associated with it include sulfur metabolism, fluorebenzoate degradation, penicillin and cephalosporin biosynthesis, beta-lactam resistance, steroid hormone biosynthesis, type II diabetes, lipid biosynthesis proteins, biosynthesis of unsaturated fatty acids, aminoacyl t-RNA synthesis, and folate synthesis. All of these were also inversely associated with *Bacillus spp.*, *Planococcaceae*, *Staphylococcus spp.*, and *Enterococcus spp.* Additional ones that were negatively associated with these bacteria include steroid biosynthesis, D-arginine and D-ornithine biosynthesis, nucleotide metabolism, biotin metabolism, sphingolipid metabolism, lysosome, other glycan degradation, valine, leucine, and isoleucine biosynthesis, glycosphingolipid metabolism, pantothenate CoA biosynthesis, and lipopolysaccharide biosynthesis. Example pathways and metabolites inversely associated with *Ruminococcus spp.* include penicillin and cephalosporin biosynthesis, nucleotide metabolism, beta-lactam

resistance, biotin metabolism, biosynthesis of unsaturated fatty acids, aminoacyl t-RNA synthesis, and folate synthesis. No associations were observed for those bacteria down-regulated in the NP group.

### *Integrative Correlation Analyses*

We used mixOmics analyses<sup>78</sup> to correlate the neurobehavioral and metabolic phenotyping and gut microbiota results with the correlation value set to  $r = 0.7$ , as recommended. As shown in **Figure 7**, *Coprobacillus spp.*, which was reduced in the NP group, positively correlated with number of Nissl positive cells. *Enterococcus spp.* and *Enterococcaceae*, both of whose relative expression were increased in NP exposed individuals, inversely correlated with body weight, fat content, and glial cell numbers. *Streptococcus*, which was increased in the NP group, negatively correlated with body weight, fat content, Nissl, and glial cell numbers.

### *Discussion*

The goals of the present study were to determine if developmental exposure of dams to silver NPs at environmentally relevant concentrations affect the microbiome-gut-brain axis and causes long-term neurobehavioral changes in mouse offspring. Further, histopathological examination of hippocampus was performed to examine the potential changes in neuronal and microglial cells due to maternal silver NP exposure.

Citrate coated spherical silver NPs are utilized for several applications. However, the developmental effects have not been clearly studied, and therefore, we examined these NPs for our present investigation.<sup>36</sup> The gastrointestinal (GI) fluid is acidic with a pH ranging from 3–7 depending upon the presence of digesta within in. The fate and the bioavailability of the

ingested particles are critically influenced by these GI tract fluids upon oral ingestion. Several groups have conducted studies to understand the integrity of silver NPs in biological fluids.<sup>84-89</sup> These studies suggest that the physiological conditions, such as presence of digesta, pH, and ionic concentrations, of the gastrointestinal tract affects NP size and coating and other various.<sup>87-93</sup> Only a handful of studies have been conducted to perform detailed investigation on the exposure effect of gastrointestinal fluids. Findings reported on citrate stabilized silver NPs (40 nm) to synthetic human stomach fluid (pH 1.5) suggest that these partially react to form aggregates along with silver chloride. However, this study may not be representative of silver NP preparations in general.<sup>87</sup> We have examined exposure of silver NP coated with polyvinyl pyrrolidone to GI fluids (at three pH concentrations 3, 7 and 9) and subsequent effects on the zeta potential and hydrodynamic diameter.<sup>61</sup> Our data show aggregation of NPs in the lower pH range, but notably, the particulate nature is maintained. Taken together, it is clear that bioavailability and accumulation of silver NPs can vary based on GI state, but, the aggregate nature of such compounds persists.

Developmental disturbances may originate due to direct and indirect effects of NP exposure. Studies show that silver NPs can be transferred from dam to offspring through the placenta and milk<sup>25</sup>, whereupon they can permeate through the blood brain barrier.<sup>26</sup> The effects of developmental exposure to silver NPs in mammals is not completely understood. Silver NP may persist for up to at least four months in the dam; whereupon, they have the potential to cross the placental barrier and accumulate in the fetus.<sup>34, 39</sup> For instance, one study that used an oral exposure approach with silver NPs in dams, who were exposed prior mating and during gestation, showed accumulation of these particles in brain and other organs of her four-day old offspring.<sup>37</sup> A short-term study using radioactive NPs, has confirmed the transport

of ~50 nm silver NPs (polyvinyl pyrrolidone coating) that maternal oral exposure leads to placental and lactational transfer and subsequent accumulation in the neonatal pup brains.<sup>35</sup>

While there have been select studies, as detailed below, examining how such direct exposure to silver NPs might affect later neurobehavioral domains, we sought to do a comprehensive assessment of such effects.

In the first set of studies, we examined whether developmental exposure to silver NPs would affect various neurobehavioral domains and metabolic parameters. Spatial navigation and learning were tested with the dry land Barnes maze. The overall trial results, however, are inconclusive, as on select trial days those exposed to silver NPs surprisingly showed some improvement over controls, but this effect was only marginal. Distance travelled was shorter for those developmentally exposed to NP, while there was no change in the velocity between the two groups. Further behavioral tests, such as the Morris Water Maze (MWM) or Y maze, are needed to validate the current findings and determine whether exposure to silver NPs affect spatial learning and memory. We opted at the outset to use the Barnes maze as it is considered more ecologically relevant for terrestrial rodents.<sup>94</sup>

In another developmental study, spatial learning and memory, as determined by the MWM, and hippocampal neuro-development appear to be altered in a dose dependent manner in offspring prenatally exposed to citrate coated silver NPs. Impaired cognition was observed at a dose of 2 mg/kg BW subcutaneous administration.<sup>34</sup> One potential explanation for differences observed in our study relative to this one is the route of administration. We used oral route of administration to mimic dietary exposure, whereas this aforementioned study subcutaneously injected the dams starting from gestational day 3 with repeat administration every 3 days up until parturition.

Anxiety-like, exploratory, and repetitive behaviors, as measured with the EPM, were also evaluated in the same groups of offspring. Head-dipping and rearing behaviors are considered repetitive behaviors. The results of our study indicate that mice developmentally exposed to NPs spent less time in head-dipping incidences compared to controls. Yet, this latter group also showed reduced duration of rearing, which is also considered as a stereotypical behavior. The incidences of NP treated offspring being immobile were greater to controls. Taken together, our findings suggest that the mice exposed to silver NPs might be more anxious and more likely to engage in at least one stereotypical behavior, head dipping. Follow-up studies, such as light-dark box (LDB) test are required to validate these initial behavioral observations.

No changes in anxiety-like behavior was observed in mice offspring as assessed by EPM and LDB test following subcutaneous exposure of NPs in prenatal stage<sup>34</sup> and oral exposure during lactation stage;<sup>38</sup> however, developmental exposure led to neural toxicity in mouse fetuses, as evidenced by mitochondrial autophagy, dysmorphology, and dysfunction of neuronal cells, blood brain barrier inflammation and astrocytic swelling.<sup>95</sup> Another study with mice suggests that prenatal exposure to silver NP (2 mg/Kg) results in increased time female but not male offspring spend immobile when tested in the forced swim test.<sup>56</sup> The finding suggests that developmental exposure to silver NPs increases depressive-like behaviors in female offspring. Dopamine is a key neurotransmitter regulating emotive behaviors, and rat offspring exposed through the dam to silver NPs have increased expression of genes involved in dopamine metabolism, including tyrosine hydroxylase (*Th*) and monoamine oxidase A (*Maoa*).<sup>57</sup>

Histological examination was performed in hippocampus region of the brain to correlate the differences in spatial, memory, behavioral and cognitive learning. There were no

significant differences in the neuronal counts between the offspring developmentally exposed to NPs and the control groups, indicating that NP exposure had minimal effect on the cognitive behavior. Microglial cells are the macrophages in central nervous system and most likely to respond when NPs enter the brain. Lower microglial counts (resident macrophages in the brain) suggest silver NP exposed offspring might be more vulnerable to pathogens. There are limited *in vivo* studies detailing how direct or developmental exposure to silver NPs might affect microglial cells in the brain. However, a review on central nervous system toxicity suggests that nanomaterials can affect microglial function.<sup>96</sup>

In this study, we used echo-MRI to assess how developmental exposure to silver NPs affect body condition. Echo-MRI indicated increased body fat content in NP exposed offspring. The increased body fat content suggests the possibility of metabolic disorders, including fatty liver disease. Such type of disorders has been reported due to oral exposure of silver NP in overweight mice.<sup>97</sup> However, additional work is needed to characterize the full extent of metabolic disruptions due to developmental exposure to silver NPs.

One of the other goals of the current set of studies was to determine whether developmental exposure to NPs could affect gut microbiota populations from weaning to adulthood in mice. Our past studies with rats examined the effects of NPs on gut microbiota focused solely on direct effects.<sup>30, 45-54, 59, 60, 98</sup> However, to the best of our knowledge, no studies have examined whether *in utero* exposure to NPs might deleteriously affect the initial bacterial colonization of the gut that would lead to permanent changes on composition of the gut flora. This issue is of critical importance given the fact that the gut microbiome can lead to profound effects on the host, including increasing the risk for neurobehavioral and metabolic disorders.<sup>61, 62, 99</sup>

The current studies clearly demonstrate that developmental exposure to silver NP induces long-term effects on gut microbiota with the greatest divergence from control mice occurring at the last timepoint assessed, 120 days of age. As shown though in the 3D PCA diagrams, at all ages tested gut bacteria within those exposed early on to silver NPs clustered separately from controls. Since, 120 days of age led to the greatest separation between these two groups and this was also around the period of the behavioral and metabolic testing, we focused on those bacteria and associated predicted metabolic pathways that differed at this timepoint. The prediction at the outset was that the antimicrobial properties of silver NPs would lead to a general reduction in most bacteria. However, the relative abundance of several bacteria was greater in the silver NP group relative to controls. These include *Prevotella spp.*, *Bacillus spp.*, *Planococcaceae*, *Staphylococcus spp.*, *Enterococcus spp.*, and *Ruminococcus spp.* The few bacteria that were reduced in those developmentally exposed to silver NP were *Coprobacillus spp.*, *Mucispirillum spp.*, and *Bifidobacterium spp.*

An increased in the relative abundance of *Prevotella spp.* in humans is associated with greater body mass index (BMI).<sup>100</sup> This bacterium is also linked with colitis and enhancement of intestinal inflammation.<sup>101</sup> An over-abundance of a *Ruminococcus spp* occurs in human patients with generalized anxiety disorder<sup>102</sup> and in children with Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).<sup>103</sup>

Of the bacteria who relative abundance is decreased in those developmentally exposed to NP, the most concerning is reductions in *Bifidobacterium spp.* Several health benefits are associated with this bacterium, and it is thus included in many probiotic treatments. One study showed that supplementation of a probiotic containing *Bifidobacterium spp* led to improved health outcomes in children with ASD and gastrointestinal disorders.<sup>104</sup> Reductions in this

bacterium may render rodent models and humans susceptible to neurobehavioral and GI diseases. If so, it would be of interest to determine whether supplementation of *Bifidobacterium* to mice developmentally exposed to NP alleviated some of their clinical signs.

PICRUSt analyses showed that several pathways were negatively associated with bacteria up-regulated in those developmentally exposed to NPs. This association means that as these bacteria increased in the NP group, such pathways are predicted to decrease. Amongst these pathways of importance is the inverse association of *Prevotella spp.* and steroid hormone biosynthesis. Steroid hormones, including testosterone and aromatization of testosterone to estrogen, is essential in regulating many key neural functions.<sup>105-108</sup> Reductions in these steroid hormones, especially estrogen, is linked to later neurobehavioral disorders, such as Alzheimer's Disease.<sup>105, 106</sup>

Biosynthesis of unsaturated fatty acids is another pathway likely reduced in response to increases in *Prevotella spp.* and *Ruminococcus spp.* Unsaturated fatty acids, in particular docosahexaenoic acid (DHA), are essential for normal cognitive functions including learning and memory, coping with stress, regulating other emotional response, inhibiting inflammation in the brain, reducing the risk of impulsive disorders, AD, and other brain disorders.<sup>109-111</sup> The findings thus suggest that NP-induced changes, including enrichment of select bacteria, may correspondingly affect metabolic pathways. Changes in such pathways may serve as one mechanism linking gut microbiome to neurobehavioral alterations.

For integrative correlation analyses with the mixOmics program, the potentially most meaningful correlation was the inverse relationship between microglial cell numbers, which were reduced in the NP group, and *Enterococcus spp.*, *Enterococcaceae*, and *Streptococcus spp.*, all three bacteria that were increased in the NP group. In general, bacterial changes are

associated with increase host inflammation.<sup>62</sup> Thus, the linkage between these bacteria and reductions in microglial cells, resident macrophages in the brain, are surprising. The findings should be taken with caution as they are only correlative. The reductions in microglial cells could also be due to effects of developmental exposure to silver NPs as shown in other studies that examined direct effects in adult rodent models.<sup>112</sup>

### ***Conclusions***

In the present study, we investigated the neurobehavioral and gut microbiota changes due to developmental exposure to silver NPs. Our results indicate that developmental exposure of silver NPs to mice can lead to increase likelihood of engaging in certain repetitive behaviors. Silver NP exposure resulted in reduction of resident microglial cells, that may render exposed offspring more vulnerable to infection. Such effects on the brain and behavioral domains might be either direct in origin or due to silver NP-induced changes on the gut microbiome. Future studies with germ-free mice will be useful in teasing apart these two potential mechanisms. The current studies though raise cause for concern that developmental exposure to silver NPs can lead to longstanding effects on the microbiome-gut-brain axis.

### ***Declaration***

The authors declare no competing financial or other interests.

### ***Acknowledgement***

This work was funded by Office of Medical Research, MU-iCATS, School of Medicine MU and C.S. Rosenfeld is supported by NIEHS 1R01ES025547.

## References

1. Castriciano, M. A., Functional Nanostructures for Sensors, Optoelectronic Devices, and Drug Delivery. *Nanomaterials (Basel)* **2020**, *10* (6).
2. Liu, J.; Sonshine, D. A.; Shervani, S.; Hurt, R. H., Controlled release of biologically active silver from nanosilver surfaces. *ACS Nano* **2010**, *4* (11), 6903-13.
3. Chen, X.; Schluesener, H. J., Nanosilver: a nanoparticle in medical application. *Toxicol Lett* **2008**, *176* (1), 1-12.
4. Chaudhry, Q.; Scotter, M.; Blackburn, J.; Ross, B.; Boxall, A.; Castle, L.; Aitken, R.; Watkins, R., Applications and implications of nanotechnologies for the food sector. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess* **2008**, *25* (3), 241-58.
5. Loeschner, K.; Hadrup, N.; Qvortrup, K.; Larsen, A.; Gao, X.; Vogel, U.; Mortensen, A.; Lam, H. R.; Larsen, E. H., Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. *Part Fibre Toxicol* **2011**, *8*, 18.
6. Quadros, M. E.; Pierson, R. t.; Tulse, N. S.; Willis, R.; Rogers, K.; Thomas, T. A.; Marr, L. C., Release of silver from nanotechnology-based consumer products for children. *Environ Sci Technol* **2013**, *47* (15), 8894-901.
7. Benn, T.; Cavanagh, B.; Hristovski, K.; Posner, J. D.; Westerhoff, P., The release of nanosilver from consumer products used in the home. *J Environ Qual* **2010**, *39* (6), 1875-82.
8. Burdusel, A. C.; Gherasim, O.; Grumezescu, A. M.; Mogoanta, L.; Ficai, A.; Andronescu, E., Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview. *Nanomaterials (Basel)* **2018**, *8* (9).
9. Paladini, F.; Pollini, M., Antimicrobial Silver Nanoparticles for Wound Healing Application: Progress and Future Trends. *Materials (Basel)* **2019**, *12* (16).
10. Kalantari, K.; Mostafavi, E.; Afifi, A. M.; Izadiyan, Z.; Jahangirian, H.; Rafiee-Moghaddam, R.; Webster, T. J., Wound dressings functionalized with silver nanoparticles: promises and pitfalls. *Nanoscale* **2020**, *12* (4), 2268-2291.
11. Boateng, J.; Catanzano, O., Silver and Silver Nanoparticle - Based Antimicrobial Dressings. In *Therapeutic Dressings and Wound Healing Applications*, Boateng, J., Ed. John Wiley and Sons Ltd: 2020.
12. Tavakoli, H.; Rastegar, H.; Taherian, M.; Samadi, M.; Rostami, H., The effect of nano-silver packaging in increasing the shelf life of nuts: An in vitro model. *Ital J Food Saf* **2017**, *6* (4), 6874.
13. Deshmukh, S. P.; Patil, S. M.; Mullani, S. B.; Delekar, S. D., Silver nanoparticles as an effective disinfectant: A review. *Mater Sci Eng C Mater Biol Appl* **2019**, *97*, 954-965.

14. Ding, R.; Yang, P.; Yang, Y.; Yang, Z.; Luo, L.; Li, H.; Wang, Q., Characterisation of silver release from nanoparticle-treated baby products. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess* **2018**, *35* (10), 2052-2061.
15. Carbone, M.; Donia, D. T.; Sabbatella, G.; Antiochia, R., Silver nanoparticles in polymeric matrices for fresh food packaging. *Journal of King Saud University - Science* **2016**, *28* (4), 273-279.
16. Rivero, P. J.; Urrutia, A.; Goicoechea, J.; Arregui, F. J., Nanomaterials for Functional Textiles and Fibers. *Nanoscale Research Letters* **2015**, *10* (1).
17. Gaillet, S.; Rouanet, J. M., Silver nanoparticles: their potential toxic effects after oral exposure and underlying mechanisms--a review. *Food Chem Toxicol* **2015**, *77*, 58-63.
18. Shahare, B.; Yashpal, M., Toxic effects of repeated oral exposure of silver nanoparticles on small intestine mucosa of mice. *Toxicol Mech Methods* **2013**, *23* (3), 161-7.
19. Sheshde, R. R. R. S. S. R. Z. A. T. S. N. S. I. A. K. S. A. R., Toxicological effects of silver nanoparticles in rats. *African Journal of Microbiology Research* **2012**, *6* (27), 5587-5593.
20. Qin, G.; Tang, S.; Li, S.; Lu, H.; Wang, Y.; Zhao, P.; Li, B.; Zhang, J.; Peng, L., Toxicological evaluation of silver nanoparticles and silver nitrate in rats following 28 days of repeated oral exposure. *Environ Toxicol* **2017**, *32* (2), 609-618.
21. Kim, Y. S.; Song, M. Y.; Park, J. D.; Song, K. S.; Ryu, H. R.; Chung, Y. H.; Chang, H. K.; Lee, J. H.; Oh, K. H.; Kelman, B. J.; Hwang, I. K.; Yu, I. J., Subchronic oral toxicity of silver nanoparticles. *Part Fibre Toxicol* **2010**, *7*, 20.
22. Bergin, I. L.; Witzmann, F. A., Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. *Int J Biomed Nanosci Nanotechnol* **2013**, *3* (1-2).
23. Boudreau, M. D.; Imam, M. S.; Paredes, A. M.; Bryant, M. S.; Cunningham, C. K.; Felton, R. P.; Jones, M. Y.; Davis, K. J.; Olson, G. R., Differential Effects of Silver Nanoparticles and Silver Ions on Tissue Accumulation, Distribution, and Toxicity in the Sprague Dawley Rat Following Daily Oral Gavage Administration for 13 Weeks. *Toxicol Sci* **2016**, *150* (1), 131-60.
24. van der Zande, M.; Vandebriel, R. J.; Van Doren, E.; Kramer, E.; Herrera Rivera, Z.; Serrano-Rojero, C. S.; Gremmer, E. R.; Mast, J.; Peters, R. J.; Hollman, P. C.; Hendriksen, P. J.; Marvin, H. J.; Peijnenburg, A. A.; Bouwmeester, H., Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. *ACS Nano* **2012**, *6* (8), 7427-42.
25. Ema, M.; Okuda, H.; Gamo, M.; Honda, K., A review of reproductive and developmental toxicity of silver nanoparticles in laboratory animals. *Reprod Toxicol* **2017**, *67*, 149-164.
26. Ahamed, M.; Alsalhi, M. S.; Siddiqui, M. K., Silver nanoparticle applications and human health. *Clin Chim Acta* **2010**, *411* (23-24), 1841-8.

27. Hadrup, N.; Lam, H. R., Oral toxicity of silver ions, silver nanoparticles and colloidal silver – A review. *Regulatory Toxicology and Pharmacology* **2014**, *68* (1), 1-7.
28. Ferdous, Z.; Nemmar, A., Health Impact of Silver Nanoparticles: A Review of the Biodistribution and Toxicity Following Various Routes of Exposure. *Int J Mol Sci* **2020**, *21* (7).
29. Li, Y.; Cummins, E., Hazard characterization of silver nanoparticles for human exposure routes. *J Environ Sci Health A Tox Hazard Subst Environ Eng* **2020**, *55* (6), 704-725.
30. Li, J.; Tang, M.; Xue, Y., Review of the effects of silver nanoparticle exposure on gut bacteria. *J Appl Toxicol* **2019**, *39* (1), 27-37.
31. Tolve, N. S.; Stefaniak, A. B.; Vance, M. E.; Rogers, K.; Mwilu, S.; LeBouf, R. F.; Schwegler-Berry, D.; Willis, R.; Thomas, T. A.; Marr, L. C., Characterization of silver nanoparticles in selected consumer products and its relevance for predicting children's potential exposures. *Int J Hyg Environ Health* **2015**, *218* (3), 345-57.
32. Park, J.; Ham, S.; Jang, M.; Lee, J.; Kim, S.; Kim, S.; Lee, K.; Park, D.; Kwon, J.; Kim, H.; Kim, P.; Choi, K.; Yoon, C., Spatial-Temporal Dispersion of Aerosolized Nanoparticles During the Use of Consumer Spray Products and Estimates of Inhalation Exposure. *Environ Sci Technol* **2017**, *51* (13), 7624-7638.
33. Williams, K.; Milner, J.; Boudreau, M. D.; Gokulan, K.; Cerniglia, C. E.; Khare, S., Effects of subchronic exposure of silver nanoparticles on intestinal microbiota and gut-associated immune responses in the ileum of Sprague-Dawley rats. *Nanotoxicology* **2015**, *9* (3), 279-89.
34. Ghaderi, S.; Tabatabaei, S. R. F.; Varzi, H. N.; Rashno, M., Induced adverse effects of prenatal exposure to silver nanoparticles on neurobehavioral development of offspring of mice. *The Journal of Toxicological Sciences* **2015**, *40* (2), 263-275.
35. Melnik, E. A.; Buzulukov, Y. P.; Demin, V. F.; Demin, V. A.; Gmoshinski, I. V.; Tyshko, N. V.; Tutelyan, V. A., Transfer of Silver Nanoparticles through the Placenta and Breast Milk during in vivo Experiments on Rats. *Acta Naturae* **2013**, *5* (3), 107-15.
36. Charehsaz, M.; Hougaard, K. S.; Sipahi, H.; Ekici, A. I.; Kaspar, C.; Culha, M.; Bucurgat, U. U.; Aydin, A., Effects of developmental exposure to silver in ionic and nanoparticle form: A study in rats. *Daru* **2016**, *24* (1), 24.
37. Lee, Y.; Choi, J.; Kim, P.; Choi, K.; Kim, S.; Shon, W.; Park, K., A transfer of silver nanoparticles from pregnant rat to offspring. *Toxicol Res* **2012**, *28* (3), 139-41.
38. Morishita, Y.; Yoshioka, Y.; Takimura, Y.; Shimizu, Y.; Namba, Y.; Nojiri, N.; Ishizaka, T.; Takao, K.; Yamashita, F.; Takuma, K.; Ago, Y.; Nagano, K.; Mukai, Y.; Kamada, H.; Tsunoda, S.-i.; Saito, S.; Matsuda, T.; Hashida, M.; Miyakawa, T.; Higashisaka, K.; Tsutsumi, Y., Distribution of Silver Nanoparticles to Breast Milk and Their Biological Effects on Breast-Fed Offspring Mice. *ACS Nano* **2016**, *10* (9), 8180-8191.

39. Wu, J.; Yu, C.; Tan, Y.; Hou, Z.; Li, M.; Shao, F.; Lu, X., Effects of prenatal exposure to silver nanoparticles on spatial cognition and hippocampal neurodevelopment in rats. *Environ Res* **2015**, *138*, 67-73.
40. Austin, C. A.; Umbreit, T. H.; Brown, K. M.; Barber, D. S.; Dair, B. J.; Francke-Carroll, S.; Feswick, A.; Saint-Louis, M. A.; Hikawa, H.; Siebein, K. N.; Goering, P. L., Distribution of silver nanoparticles in pregnant mice and developing embryos. *Nanotoxicology* **2012**, *6*, 912-22.
41. Austin, C. A.; Hinkley, G. K.; Mishra, A. R.; Zhang, Q.; Umbreit, T. H.; Betz, M. W.; B, E. W.; Casey, B. J.; Francke-Carroll, S.; Hussain, S. M.; Roberts, S. M.; Brown, K. M.; Goering, P. L., Distribution and accumulation of 10 nm silver nanoparticles in maternal tissues and visceral yolk sac of pregnant mice, and a potential effect on embryo growth. *Nanotoxicology* **2016**, *10* (6), 654-61.
42. Wang, Z.; Qu, G.; Su, L.; Wang, L.; Yang, Z.; Jiang, J.; Liu, S.; Jiang, G., Evaluation of the biological fate and the transport through biological barriers of nanosilver in mice. *Curr Pharm Des* **2013**, *19* (37), 6691-7.
43. Yu, W. J.; Son, J. M.; Lee, J.; Kim, S. H.; Lee, I. C.; Baek, H. S.; Shin, I. S.; Moon, C.; Kim, S. H.; Kim, J. C., Effects of silver nanoparticles on pregnant dams and embryo-fetal development in rats. *Nanotoxicology* **2014**, *8 Suppl 1*, 85-91.
44. Korani, M.; Ghazizadeh, E.; Korani, S.; Hami, Z.; Mohammadi-Bardbori, A., Effects of silver nanoparticles on human health. *European Journal of Nanomedicine* **2015**, *7* (1).
45. Gonzalez, E. A.; Carty, D. R.; Tran, F. D.; Cole, A. M.; Lein, P. J., Developmental exposure to silver nanoparticles at environmentally relevant concentrations alters swimming behavior in zebrafish (*Danio rerio*). *Environ Toxicol Chem* **2018**, *37* (12), 3018-3024.
46. Orbea, A.; Gonzalez-Soto, N.; Lacave, J. M.; Barrio, I.; Cajaraville, M. P., Developmental and reproductive toxicity of PVP/PEI-coated silver nanoparticles to zebrafish. *Comp Biochem Physiol C Toxicol Pharmacol* **2017**, *199*, 59-68.
47. Buric, P.; Jaksic, Z.; Stajner, L.; Dutour Sikiric, M.; Jurasin, D.; Cascio, C.; Calzolari, L.; Lyons, D. M., Effect of silver nanoparticles on Mediterranean sea urchin embryonal development is species specific and depends on moment of first exposure. *Mar Environ Res* **2015**, *111*, 50-9.
48. Han, X.; Geller, B.; Moniz, K.; Das, P.; Chippindale, A. K.; Walker, V. K., Monitoring the developmental impact of copper and silver nanoparticle exposure in *Drosophila* and their microbiomes. *Sci Total Environ* **2014**, *487*, 822-9.
49. Xin, Q.; Rotchell, J. M.; Cheng, J.; Yi, J.; Zhang, Q., Silver nanoparticles affect the neural development of zebrafish embryos. *J Appl Toxicol* **2015**, *35* (12), 1481-92.
50. Lee, K. J.; Browning, L. M.; Nallathamby, P. D.; Osgood, C. J.; Xu, X. H., Silver nanoparticles induce developmental stage-specific embryonic phenotypes in zebrafish. *Nanoscale* **2013**, *5* (23), 11625-36.

51. Browning, L. M.; Lee, K. J.; Nallathamby, P. D.; Xu, X. H., Silver nanoparticles incite size- and dose-dependent developmental phenotypes and nanotoxicity in zebrafish embryos. *Chem Res Toxicol* **2013**, *26* (10), 1503-13.
52. Asharani, P. V.; Lianwu, Y.; Gong, Z.; Valiyaveettil, S., Comparison of the toxicity of silver, gold and platinum nanoparticles in developing zebrafish embryos. *Nanotoxicology* **2011**, *5* (1), 43-54.
53. Powers, C. M.; Slotkin, T. A.; Seidler, F. J.; Badireddy, A. R.; Padilla, S., Silver nanoparticles alter zebrafish development and larval behavior: distinct roles for particle size, coating and composition. *Neurotoxicol Teratol* **2011**, *33* (6), 708-14.
54. Powers, C. M.; Levin, E. D.; Seidler, F. J.; Slotkin, T. A., Silver exposure in developing zebrafish produces persistent synaptic and behavioral changes. *Neurotoxicol Teratol* **2011**, *33* (2), 329-32.
55. Amiri, S.; Yousefi-Ahmadipour, A.; Hosseini, M. J.; Haj-Mirzaian, A.; Momeny, M.; Hosseini-Chegeni, H.; Mokhtari, T.; Kharrazi, S.; Hassanzadeh, G.; Amini, S. M.; Jafarinejad, S.; Ghazi-Khansari, M., Maternal exposure to silver nanoparticles are associated with behavioral abnormalities in adulthood: Role of mitochondria and innate immunity in developmental toxicity. *Neurotoxicology* **2018**, *66*, 66-77.
56. Tabatabaei, S. R.; Moshrefi, M.; Askaripour, M., Prenatal Exposure to Silver Nanoparticles Causes Depression Like Responses in Mice. *Indian J Pharm Sci* **2015**, *77* (6), 681-6.
57. Fatemi Tabatabaie, S. R.; Mehdiabadi, B.; Moori Bakhtiari, N.; Tabandeh, M. R., Silver nanoparticle exposure in pregnant rats increases gene expression of tyrosine hydroxylase and monoamine oxidase in offspring brain. *Drug Chem Toxicol* **2017**, *40* (4), 440-447.
58. Skalska, J.; Frontczak-Baniewicz, M.; Struzynska, L., Synaptic degeneration in rat brain after prolonged oral exposure to silver nanoparticles. *Neurotoxicology* **2015**, *46*, 145-54.
59. van den Brule, S.; Ambroise, J.; Lecloux, H.; Levard, C.; Soulas, R.; De Temmerman, P. J.; Palmari-Pallag, M.; Marbaix, E.; Lison, D., Dietary silver nanoparticles can disturb the gut microbiota in mice. *Part Fibre Toxicol* **2016**, *13* (1), 38.
60. Pranab Das, J. A. K. M., Elaine O. Petrof, Emma Allen-Vercoe, Virginia K. Walker, Nanosilver-Mediated Change in Human Intestinal Microbiota. *Journal of Nanomedicine & Nanotechnology* **2014**.
61. Javurek, A. B.; Suresh, D.; Spollen, W. G.; Hart, M. L.; Hansen, S. A.; Ellersieck, M. R.; Bivens, N. J.; Givan, S. A.; Upendran, A.; Kannan, R.; Rosenfeld, C. S., Gut Dysbiosis and Neurobehavioral Alterations in Rats Exposed to Silver Nanoparticles. *Sci Rep* **2017**, *7* (1), 2822.
62. Rosenfeld, C. S., Microbiome Disturbances and Autism Spectrum Disorders. *Drug Metab Dispos* **2015**, *43* (10), 1557-71.

63. Borre, Y. E.; Moloney, R. D.; Clarke, G.; Dinan, T. G.; Cryan, J. F., The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. *Adv Exp Med Biol* **2014**, *817*, 373-403.
64. Clarke, G.; Grenham, S.; Scully, P.; Fitzgerald, P.; Moloney, R. D.; Shanahan, F.; Dinan, T. G.; Cryan, J. F., The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. *Mol Psychiatry* **2013**, *18* (6), 666-73.
65. Stilling, R. M.; Dinan, T. G.; Cryan, J. F., Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis. *Genes Brain Behav* **2014**, *13* (1), 69-86.
66. Cumberland, S. A.; Lead, J. R., Particle size distributions of silver nanoparticles at environmentally relevant conditions. *J Chromatogr A* **2009**, *1216* (52), 9099-105.
67. Magoc, T.; Salzberg, S. L., FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics* **2011**, *27* (21), 2957-63.
68. Edgar, R. C., Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **2010**, *26* (19), 2460-1.
69. DeSantis, T. Z.; Hugenholtz, P.; Larsen, N.; Rojas, M.; Brodie, E. L.; Keller, K.; Huber, T.; Dalevi, D.; Hu, P.; Andersen, G. L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl Environ Microbiol* **2006**, *72* (7), 5069-72.
70. Caporaso, J. G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F. D.; Costello, E. K.; Fierer, N.; Pena, A. G.; Goodrich, J. K.; Gordon, J. I.; Huttley, G. A.; Kelley, S. T.; Knights, D.; Koenig, J. E.; Ley, R. E.; Lozupone, C. A.; McDonald, D.; Muegge, B. D.; Pirrung, M.; Reeder, J.; Sevinsky, J. R.; Turnbaugh, P. J.; Walters, W. A.; Widmann, J.; Yatsunencko, T.; Zaneveld, J.; Knight, R., QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* **2010**, *7* (5), 335-6.
71. Bolyen, E.; Rideout, J. R.; Dillon, M. R.; Bokulich, N. A.; Abnet, C. C.; Al-Ghalith, G. A.; Alexander, H.; Alm, E. J.; Arumugam, M.; Asnicar, F.; Bai, Y.; Bisanz, J. E.; Bittinger, K.; Brejnrod, A.; Brislawn, C. J.; Brown, C. T.; Callahan, B. J.; Caraballo-Rodriguez, A. M.; Chase, J.; Cope, E. K.; Da Silva, R.; Diener, C.; Dorrestein, P. C.; Douglas, G. M.; Durall, D. M.; Duvallet, C.; Edwardson, C. F.; Ernst, M.; Estaki, M.; Fouquier, J.; Gauglitz, J. M.; Gibbons, S. M.; Gibson, D. L.; Gonzalez, A.; Gorlick, K.; Guo, J.; Hillmann, B.; Holmes, S.; Holste, H.; Huttenhower, C.; Huttley, G. A.; Janssen, S.; Jarmusch, A. K.; Jiang, L.; Kaehler, B. D.; Kang, K. B.; Keefe, C. R.; Keim, P.; Kelley, S. T.; Knights, D.; Koester, I.; Kosciulek, T.; Kreps, J.; Langille, M. G. I.; Lee, J.; Ley, R.; Liu, Y. X.; Loftfield, E.; Lozupone, C.; Maher, M.; Marotz, C.; Martin, B. D.; McDonald, D.; McIver, L. J.; Melnik, A. V.; Metcalf, J. L.; Morgan, S. C.; Morton, J. T.; Naimey, A. T.; Navas-Molina, J. A.; Nothias, L. F.; Orchanian, S. B.; Pearson, T.; Peoples, S. L.; Petras, D.; Preuss, M. L.; Priesse, E.; Rasmussen, L. B.; Rivers, A.; Robeson, M. S., 2nd; Rosenthal, P.; Segata, N.; Shaffer, M.; Shiffer, A.; Sinha, R.; Song, S. J.; Spear, J. R.; Swafford, A. D.; Thompson, L. R.; Torres, P. J.; Trinh, P.; Tripathi, A.; Turnbaugh, P. J.; Ul-Hasan, S.; van der Hooft, J. J. J.; Vargas, F.; Vazquez-Baeza, Y.; Vogtmann, E.; von Hippel, M.; Walters, W.; Wan, Y.; Wang, M.; Warren, J.; Weber, K. C.; Williamson, C. H. D.; Willis, A. D.; Xu, Z. Z.; Zaneveld, J. R.; Zhang, Y.; Zhu, Q.; Knight, R.; Caporaso, J. G., Reproducible,

interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol* **2019**, *37* (8), 852-857.

72. Segata, N.; Izard, J.; Waldron, L.; Gevers, D.; Miropolsky, L.; Garrett, W. S.; Huttenhower, C., Metagenomic biomarker discovery and explanation. *Genome Biol* **2011**, *12* (6), R60.

73. Eren, A. M.; Esen, O. C.; Quince, C.; Vineis, J. H.; Morrison, H. G.; Sogin, M. L.; Delmont, T. O., Anvi'o: an advanced analysis and visualization platform for 'omics data. *PeerJ* **2015**, *3*, e1319.

74. Langille, M. G.; Zaneveld, J.; Caporaso, J. G.; McDonald, D.; Knights, D.; Reyes, J. A.; Clemente, J. C.; Burkepille, D. E.; Vega Thurber, R. L.; Knight, R.; Beiko, R. G.; Huttenhower, C., Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* **2013**, *31* (9), 814-21.

75. Love, M. I.; Huber, W.; Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **2014**, *15* (12), 550.

76. Javurek, A. B.; Spollen, W. G.; Ali, A. M.; Johnson, S. A.; Lubahn, D. B.; Bivens, N. J.; Bromert, K. H.; Ellersieck, M. R.; Givan, S. A.; Rosenfeld, C. S., Discovery of a Novel Seminal Fluid Microbiome and Influence of Estrogen Receptor Alpha Genetic Status. *Sci Rep* **2016**, *6*, 23027.

77. Javurek, A. B.; Spollen, W. G.; Johnson, S. A.; Bivens, N. J.; Bromert, K. H.; Givan, S. A.; Rosenfeld, C. S., Effects of exposure to bisphenol A and ethinyl estradiol on the gut microbiota of parents and their offspring in a rodent model. *Gut Microbes* **2016**, *7* (6), 471-485.

78. Rohart, F.; Gautier, B.; Singh, A.; Le Cao, K.-A., mixOmics: An R package for 'omics feature selection and multiple data integration. *PLoS computational biology* **2017**, *13* (11), e1005752.

79. González, I.; Lê Cao, K.-A.; Davis, M. J.; Déjean, S., Visualising associations between paired 'omics' data sets. *BioData mining* **2012**, *5* (1), 19.

80. Johnson, S. A.; Farrington, M. J.; Murphy, C. R.; Caldo, P. D.; McAllister, L. A.; Kaur, S.; Chun, C.; Ortega, M. T.; Marshall, B. L.; Hoffmann, F.; Ellersieck, M. R.; Schenk, A. K.; Rosenfeld, C. S., Multigenerational effects of bisphenol A or ethinyl estradiol exposure on F2 California mice (*Peromyscus californicus*) pup vocalizations. *PLoS One* **2018**, *13* (6), e0199107.

81. Marshall, B. L.; Liu, Y.; Farrington, M. J.; Mao, J.; Helferich, W. G.; Schenk, A. K.; Bivens, N. J.; Sarma, S. J.; Lei, Z.; Sumner, L. W.; Joshi, T.; Rosenfeld, C. S., Early genistein exposure of California mice and effects on the gut microbiota-brain axis. *J Endocrinol* **2019**, *242* (2), 139-157.

82. Chew, V.; Service, U. S. A. R., *Comparisons Among Treatment Means in an Analysis of Variance*. Department of Agriculture, Agricultural Research Service: 1977.

83. Saville, D. J., Multiple Comparison Procedures: The Practical Solution. *The American Statistician* **1990**, *44* (2).
84. Axson, J. L.; Stark, D. I.; Bondy, A. L.; Capracotta, S. S.; Maynard, A. D.; Philbert, M. A.; Bergin, I. L.; Ault, A. P., Rapid Kinetics of Size and pH-Dependent Dissolution and Aggregation of Silver Nanoparticles in Simulated Gastric Fluid. *The Journal of Physical Chemistry C* **2015**, *119* (35), 20632-20641.
85. Tai, J.-T.; Lai, C.-S.; Ho, H.-C.; Yeh, Y.-S.; Wang, H.-F.; Ho, R.-M.; Tsai, D.-H., Protein–Silver Nanoparticle Interactions to Colloidal Stability in Acidic Environments. *Langmuir* **2014**, *30* (43), 12755-12764.
86. Badawy, A. M. E.; Luxton, T. P.; Silva, R. G.; Scheckel, K. G.; Suidan, M. T.; Tolaymat, T. M., Impact of Environmental Conditions (pH, Ionic Strength, and Electrolyte Type) on the Surface Charge and Aggregation of Silver Nanoparticles Suspensions. *Environmental Science & Technology* **2010**, *44* (4), 1260-1266.
87. Mwilu, S. K.; El Badawy, A. M.; Bradham, K.; Nelson, C.; Thomas, D.; Scheckel, K. G.; Tolaymat, T.; Ma, L.; Rogers, K. R., Changes in silver nanoparticles exposed to human synthetic stomach fluid: Effects of particle size and surface chemistry. *Science of The Total Environment* **2013**, *447*, 90-98.
88. Rogers, K. R.; Bradham, K.; Tolaymat, T.; Thomas, D. J.; Hartmann, T.; Ma, L.; Williams, A., Alterations in physical state of silver nanoparticles exposed to synthetic human stomach fluid. *Science of The Total Environment* **2012**, *420*, 334-339.
89. Walczak, A. P.; Fokkink, R.; Peters, R.; Tromp, P.; Herrera Rivera, Z. E.; Rietjens, I. M. C. M.; Hendriksen, P. J. M.; Bouwmeester, H., Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. *Nanotoxicology* **2012**, *7* (7), 1198-1210.
90. Stebounova, L. V.; Guio, E.; Grassian, V. H., Silver nanoparticles in simulated biological media: a study of aggregation, sedimentation, and dissolution. *Journal of Nanoparticle Research* **2010**, *13* (1), 233-244.
91. Hua, S., Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors. *Frontiers in Pharmacology* **2020**, *11*.
92. Laloux, L.; Kastrati, D.; Cambier, S.; Gutleb, A. C.; Schneider, Y. J., The Food Matrix and the Gastrointestinal Fluids Alter the Features of Silver Nanoparticles. *Small* **2020**, *16* (21).
93. Cueva, C.; Gil-Sánchez, I.; Tamargo, A.; Miralles, B.; Crespo, J.; Bartolomé, B.; Moreno-Arribas, M. V., Gastrointestinal digestion of food-use silver nanoparticles in the dynamic SIMulator of the GastroIntestinal tract (simgi®). Impact on human gut microbiota. *Food and Chemical Toxicology* **2019**, *132*.
94. Rosenfeld, C. S.; Ferguson, S. A., Barnes maze testing strategies with small and large rodent models. *J Vis Exp* **2014**, (84), e51194.

95. Fennell, T. R.; Mortensen, N. P.; Black, S. R.; Snyder, R. W.; Levine, K. E.; Poitras, E.; Harrington, J. M.; Wingard, C. J.; Holland, N. A.; Pathmasiri, W.; Sumner, S. C. J., Disposition of intravenously or orally administered silver nanoparticles in pregnant rats and the effect on the biochemical profile in urine. *Journal of Applied Toxicology* **2017**, *37* (5), 530-544.
96. Wei, L.; shao, l.; Feng, X.; Chen, A.; Zhang, Y.; Wang, J., Central nervous system toxicity of metallic nanoparticles. *International Journal of Nanomedicine* **2015**.
97. Jia, J.; Li, F.; Zhou, H.; Bai, Y.; Liu, S.; Jiang, Y.; Jiang, G.; Yan, B., Oral Exposure to Silver Nanoparticles or Silver Ions May Aggravate Fatty Liver Disease in Overweight Mice. *Environmental Science & Technology* **2017**, *51* (16), 9334-9343.
98. Philbrook, N. A.; Winn, L. M.; Afrooz, A. R.; Saleh, N. B.; Walker, V. K., The effect of TiO<sub>2</sub> and Ag nanoparticles on reproduction and development of *Drosophila melanogaster* and CD-1 mice. *Toxicol Appl Pharmacol* **2011**, *257* (3), 429-36.
99. Rosenfeld, C. S., Effects of Phytoestrogens on the Developing Brain, Gut Microbiota, and Risk for Neurobehavioral Disorders. *Frontiers in Nutrition* **2019**, *6*.
100. Stanislawski, M. A.; Dabelea, D.; Lange, L. A.; Wagner, B. D.; Lozupone, C. A., Gut microbiota phenotypes of obesity. *NPJ Biofilms Microbiomes* **2019**, *5* (1), 18.
101. Iljazovic, A.; Roy, U.; Gálvez, E. J. C.; Lesker, T. R.; Zhao, B.; Gronow, A.; Amend, L.; Will, S. E.; Hofmann, J. D.; Pils, M. C.; Schmidt-Hohagen, K.; Neumann-Schaal, M.; Strowig, T., Perturbation of the gut microbiome by *Prevotella* spp. enhances host susceptibility to mucosal inflammation. *Mucosal Immunology* **2020**.
102. Jiang, H.-y.; Zhang, X.; Yu, Z.-h.; Zhang, Z.; Deng, M.; Zhao, J.-h.; Ruan, B., Altered gut microbiota profile in patients with generalized anxiety disorder. *Journal of Psychiatric Research* **2018**, *104*, 130-136.
103. Heimesaat, Markus M.; De Angelis, M.; Piccolo, M.; Vannini, L.; Siragusa, S.; De Giacomo, A.; Serrazanetti, D. I.; Cristofori, F.; Guerzoni, M. E.; Gobbetti, M.; Francavilla, R., Fecal Microbiota and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified. *PLoS ONE* **2013**, *8* (10).
104. Arnold, L. E.; Luna, R. A.; Williams, K.; Chan, J.; Parker, R. A.; Wu, Q.; Hollway, J. A.; Jeffs, A.; Lu, F.; Coury, D. L.; Hayes, C.; Savidge, T., Probiotics for Gastrointestinal Symptoms and Quality of Life in Autism: A Placebo-Controlled Pilot Trial. *Journal of Child and Adolescent Psychopharmacology* **2019**, *29* (9), 659-669.
105. Shay, D. A.; Vieira-Potter, V. J.; Rosenfeld, C. S., Sexually Dimorphic Effects of Aromatase on Neurobehavioral Responses. *Frontiers in Molecular Neuroscience* **2018**, *11*.
106. Rosenfeld, C. S.; Shay, D. A.; Vieira-Potter, V. J., Cognitive Effects of Aromatase and Possible Role in Memory Disorders. *Frontiers in Endocrinology* **2018**, *9*.

107. Kight, K. E.; McCarthy, M. M., Androgens and the developing hippocampus. *Biology of Sex Differences* **2020**, *11* (1).
108. Spritzer, M. D.; Roy, E. A., Testosterone and Adult Neurogenesis. *Biomolecules* **2020**, *10* (2).
109. Sinclair, A. J., Docosahexaenoic acid and the brain- what is its role? *Asia Pac J Clin Nutr* **2019**, *28* (4), 675-688.
110. Mallick, R.; Basak, S.; Duttaroy, A. K., Docosahexaenoic acid,22:6n-3: Its roles in the structure and function of the brain. *Int J Dev Neurosci* **2019**, *79*, 21-31.
111. Simonetto, M.; Infante, M.; Sacco, R. L.; Rundek, T.; Della-Morte, D., A Novel Anti-Inflammatory Role of Omega-3 PUFAs in Prevention and Treatment of Atherosclerosis and Vascular Cognitive Impairment and Dementia. *Nutrients* **2019**, *11* (10).
112. Lamas, B.; Martins Breyner, N.; Houdeau, E., Impacts of foodborne inorganic nanoparticles on the gut microbiota-immune axis: potential consequences for host health. *Particle and Fibre Toxicology* **2020**, *17* (1).
113. Ma, J.; Prince, A. L.; Bader, D.; Hu, M.; Ganu, R.; Baquero, K.; Blundell, P.; Alan Harris, R.; Frias, A. E.; Grove, K. L.; Aagaard, K. M., High-fat maternal diet during pregnancy persistently alters the offspring microbiome in a primate model. *Nat Commun* **2014**, *5*, 3889.

**FIGURES:**




Figure 1. EPM results: (a) Time spent head dipping, (b) Time spent rearing and, (c) Frequency of remaining immobile. *p* value differences are designated above the graphs. Replicates tested include n=11 for Ctrl; n=12 for NP.




Figure 2. Nissl and Glial staining results: (a) Nissl positive cells and (b) Microglial positive cells.  $p$  value differences are designated above the graphs. Replicates tested include;  $n=11$  for Ctrl;  $n=12$  for NP.




Figure 3. Echo-MRI results for: (a) Total fat content and (b) Total water.  $p$  value differences are designated above the graphs. Replicates tested include  $n=11$  for Ctrl;  $n=12$  for NP.




Figure 4. 3D PCA plots to show  $\beta$ -diversity. Figure shows results for Control and NP groups at 30, 60, 90, and 120 days of age. PERMANOVA values: Replicates tested include Ctrl and NP groups respectively at 30 (n=10 and n=9), 60 (n=11 and n=11), 90 (n=12 and n=10), and 120 (n=10 and n=12) days of age. 30 days of age  $p = 0.027$ , 60 days of age  $p = 0.001$ , 90 days of age  $p = 0.002$ , and 120 days of age  $p = 0.006$ . Each circle represents a single replicate.




Figure 5. LEfSe analyses for bacterial differences at 120 days of age. Bacteria shown in green bars are greater in NP group; whereas those shown in red are greater in control (Ctrl) group. Replicates tested include n=12 for NP; n=10 for Ctrl.




Figure 6. Bacterial metabolic and other pathway differences in the fecal microbiome of NP vs. Ctrl. As described in Fig. 7 of Ma *et al.*<sup>103</sup>, correlations between the PICRUS t-generated functional profile and QIIME-generated genus level bacterial abundance were calculated and plotted against treatment group. Those genera that were identified by LefSe as being different between the two groups are depicted. Bacteria that are highlighted had increased relative amounts in NP group. Metabolic pathway designations are delineated at the top of the figure. Shading intensity and size of the circles indicates the Kendall rank correlation coefficient between matrices. Red indicates a positive correlation; whereas blue designates a negative correlation. Red squares surrounding the circles are indicative of a P value  $\leq 0.05$ . Legend for the quantitative scores associated with the range of blue to red colors is listed below the figure.




Figure 7. Circos plot correlations between gut bacterial, brain histological analyses, and behavioral parameters in NP vs. Ctrl. Red lines in the center indicate a positive correlation. In contrast, blue lines indicate a negative correlation. Results for AIN females are indicated with a blue line outside of the circle. Orange line indicates results for GEN females. The color of the line further from the circle indicates the group where these results are greater.

# Figures




Figure 1

EPM results: (a) Time spent head dipping, (b) Time spent rearing and, (c) Frequency of remaining immobile. p value differences are designated above the graphs. Replicates tested include n=11 for Ctrl; n=12 for NP.






Figure 2

Nissl and Glial staining results: (a) Nissl positive cells and (b) Microglial positive cells. p value differences are designated above the graphs. Replicates tested include; n=11 for Ctrl; n=12 for NP.




**Figure 3**

Echo-MRI results for: (a) Total fat content and (b) Total water. p value differences are designated above the graphs. Replicates tested include n=11 for Ctrl; n=12 for NP.



**Figure 4**


3D PCA plots to show  $\beta$ -diversity. Figure shows results for Control and NP groups at 30, 60, 90, and 120 days of age. PERMANOVA values: Replicates tested include Ctrl and NP groups respectively at 30 (n=10 and n=9), 60 (n=11 and n=11), 90 (n=12 and n=10), and 120 (n=10 and n=12) days of age. 30 days of age p = 0.027, 60 days of age p = 0.001, 90 days of age p = 0.002, and 120 days of age p = 0.006. Each circle represents a single replicate.



**Figure 5**

LEfSe analyses for bacterial differences at 120 days of age. Bacteria shown in green bars are greater in NP group; whereas those shown in red are greater in control (Ctrl) group. Replicates tested include n=12 for NP; n=10 for Ctrl.





**Figure 7**

Circos plot correlations between gut bacterial, brain histological analyses, and behavioral parameters in NP vs. Ctrl. Red lines in the center indicate a positive correlation. In contrast, blue lines indicate a negative correlation. Results for AIN females are indicated with a blue line outside of the circle. Orange line indicates results for GEN females. The color of the line further from the circle indicates the group where these results are greater.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFile.docx](#)